Holen Sie sich die Stockscreener-App
7.98
8.06%
-0.70
Handel nachbörslich:
7.99
0.010
+0.13%
Immix Biopharma Inc Aktie (IMMX) Neueste Nachrichten
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Immix Biopharma to Participate in the 45th Annual J.P.... - t.co
San Francisco will host Immix Biopharma’s presentation Jan. 11–14. - Stock Titan
Immix Biopharma Prices $125 Million Equity Offering - The Globe and Mail
Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock - TradingView
Immix Biopharma closes $117.1m stock offering By Investing.com - Investing.com Nigeria
Immix Biopharma Closes $117.1 Million Underwritten Registered Offering - Quiver Quantitative
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock - GlobeNewswire
Immix plans to use about $117 million for treatment development and company operations - Stock Titan
Immunome (IMNM) Is Down 6.5% After FDA Clears IND For Novel ADC IM-1340 Trial – Has The Bull Case Changed? - Yahoo Finance
Immix Biopharma Reports 89% Complete Response Rate in Phase 2 NXC-201 Trial - Yahoo Finance
Immix Biopharma prices $125M stock offering at $11 per share - Investing.com Nigeria
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock - GlobeNewswire
All 25 new patients had a complete response or tested negative for remaining disease - Stock Titan
IMMXAL Amyloidosis CAR T Platform And Regulatory Tailwinds Will Drive Long-Term Opportunity - Simply Wall Street
Immix Biopharma (Nasdaq:IMMX)Stock Analysis - Simply Wall Street
Immix Biopharma (NasdaqCM:IMMX) Stock Price - Simply Wall Street
Immix Biopharma (IMMX) Holds at $13.77: Biotech Stock Navigates Tight Trading RangeBeta Neutral Pair - dars.gov.et
Immix Biopharma (IMMX) Holds at $13.77: Biotech Stock Navigates Tight Trading RangeSign of Strength - dars.gov.et
Immix Biopharma (IMMX) Holds at $13.77: Biotech Stock Navigates Tight Trading RangeIndex Put Call - siam.in
Immix (IMMX) Today: Moves 1.32% Lower to $13.48 at the Close; Chart Watch: the Price Remains Bounded by the Supplied Support and Resistance in the Available RecordUp Down Volume - vinanet.vn
Tocqueville Asset Management L.P. Buys New Position in Immix Biopharma, Inc. $IMMX - MarketBeat
Blue Owl Capital Holdings LP Makes New $4.51 Million Investment in Immix Biopharma, Inc. $IMMX - MarketBeat
Immix (IMMX) Quarterly Scorecard: The Available Figures Are Largely in Line on the Day; Session Move: Shares Fall 1.21% in the Current UpdatePre-Earnings Setup - vinanet.vn
Immix Biopharma (NASDAQ:IMMX) Sets New 12-Month HighStill a Buy? - MarketBeat
Analysts Offer Insights on Healthcare Companies: AEON Biopharma (AEON) and Immix Biopharma (IMMX) - The Globe and Mail
Immix Biopharma Stock Price Forecast. Should You Buy IMMX? - StockInvest.us
Immix Biopharma (NASDAQ:IMMX) Stock Price Down 4.5%Here's Why - MarketBeat
Immix Biopharma (IMMX) gains 5.6% stake holder led by Eventide Asset Management - Stock Titan
Citizens reiterates Immix Biopharma stock rating on pipeline progress By Investing.com - Investing.com Australia
Citizens reiterates Immix Biopharma stock rating on pipeline progress - Investing.com
Citizens reiterates Immix Biopharma stock rating on pipeline progress By Investing.com - Investing.com Canada
Citizens reiterates Immix Biopharma stock rating on pipeline progress By Investing.com - Investing.com India
Citizens reiterates Immix Biopharma stock rating on pipeline progress By Investing.com - Investing.com UK
Citizens reiterates Immix Biopharma stock rating on pipeline progress - Investing.com
Janus Henderson Group (IMMX) discloses 9.78M-share beneficial stake in Immix Biopharma - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc.IMMX - PR Newswire
Immix Biopharma Q3 EPS Estimate Lowered by HC Wainwright - MarketBeat
Immix Biopharma (NASDAQ:IMMX) Trading 7.1% HigherStill a Buy? - MarketBeat
HC Wainwright Estimates Immix Biopharma FY2027 Earnings - MarketBeat
Immix Biopharma publishes corporate presentation on NXC-201 BCMA CAR-T in relapsed/refractory AL amyloidosis - Bitget
Immix Biopharma, Inc. Stock 12‑Month Price Target Cut to $20.44, Implies 102% Upside - TradingView
Morgan Stanley Adjusts PT on Immix Biopharma to $19 From $20, Maintains Overweight Rating - marketscreener.com
Morgan Stanley Adjusts PT on Immix Biopharma to $19 From $20, Maintains Overweight Rating - Moomoo
IMMIX BIOPHARMA, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $25 FROM $20 - Bitget
H.C. Wainwright raises Immix Biopharma price target to $25 By Investing.com - Investing.com Australia
H.C. Wainwright raises Immix Biopharma price target to $25 By Investing.com - Investing.com South Africa
H.C. Wainwright raises Immix Biopharma price target to $25 By Investing.com - Investing.com Nigeria
H.C. Wainwright raises Immix Biopharma price target to $25 - Investing.com India
H.C. Wainwright raises Immix Biopharma price target to $25 - Investing.com
2.80%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):